Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease

Neuropharmacology

Volumn 53, Issue 1, 2007, Pages 125-133

  Zhang, Hai ^a   Ma, Liqun ^a   Wang, Fang ^a   Chen, Jianguo ^a   Zhen, Xuechu ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Dopamine receptor; Dyskinesia; Immediate early gene; l dihydroxyphenylalanine (L DOPA); Parkinson's disease; SKF83959

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE; DESIPRAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; MESULERGINE; OXIDOPAMINE; PRAZOSIN; SEROTONIN ANTAGONIST; SPIPERONE; TRANSCRIPTION FACTOR FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG MECHANISM; DYSKINESIA; GENE EXPRESSION; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MOVEMENT; OXIDOPAMINE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; SPIPERONE; SYMPATHOLYTICS; TIME FACTORS;

EID: 34547170139     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.04.004     Document Type: Article

References (45)

1. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiology of Disease 6 (1999) 461-474
2. Andersson M., Konradi C., and Cenci M.A. cAMP response element binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-deinnervated striatum. The Journal of Neuroscience 21 (2001) 9930-9943
3. Andringa G., Drukarch B., Leyen J.E., Cools A.R., and Stoof J.C. The alleged dopamine D1 receptor agonist SKF83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. European Journal of Pharmacology 364 (1999) 33-41
4. Andringa G., Stoof J.C., and Cools A.R. Sub-chronic administration of the dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology 146 (1999) 328-334
5. Bedard P.J., Di Paolo T., Falardeau P., and Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Research 379 (1986) 294-299
6. Blanchet P.J., Grondin R., and Bedard P.J. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Movement Disorders 11 (1996) 91-94
7. Boraud T., Bezard E., Bioulac B., and Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124 (2001) 546-557
8. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders 20 (2005) 919-931
9. Cenci M.A., Lee C.S., and Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. European Journal of Neuroscience 10 (1998) 2694-2706
10. Cenci M.A., Tranberg A., Andersson M., and Hilbertson A. Changes in the regional and compartmental distribution of FosB and JunB-like immunoreactivity induced in the dopamine denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94 (1999) 515-527
11. Clarke C.E., Sambrook M.A., Mitchell I.J., and Crossman A.R. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP). Journal of the Neurological Sciences 78 (1987) 273-280
12. Clifford J.J., Tighe O., Croke D.T., Kinsella A., Sibley D.R., Drago J., and Waddington J.L. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93 (1999) 1483-1489
13. Cole D.G., Kobierski L.A., Konradi C., and Hyman S.E. 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons. Proceedings of the National Academy of Sciences 91 (1994) 9631-9635
14. Deveney A.M., and Waddington J.L. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. British Journal of Pharmacology 116 (1995) 2120-2126
15. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. Journal of Neurology 252 Suppl. 4 (2005) IV/37-IV/42
16. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 Dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. The Journal of Neuroscience 22 (2002) 5042-5054
17. Gnanalingham K.K., Erol D.D., Hunter A.J., Smith L.A., Jenner P., and Marsden C.D. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl.) 117 (1995) 275-286
18. Gnanalingham K.K., Hunter A.J., Jenner P., and Marsden C.D. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117 (1995) 287-297
19. Gnanalingham K.K., Hunter A.J., Jenner P., and Marsden C.D. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease-the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology (Berl.) 117 (1995) 403-412
20. Gnanalingham K.K., Hunter A.J., Jenner P., and Marsden C.D. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat-relationship to circling behaviour. Biochemical Pharmacology 49 (1995) 1185-1193
21. Jin L., Goswami S., Cai G., Zhen X., and Friedman E. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. Journal of Neurochemistry 85 (2003) 378-386
22. Kurth M.C., Tetrud J.W., Tanner C.M., Irwin I., Stebbins G.T., Goetz C.G., and Langston J.W. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 43 (1993) 1698-1703
23. Lee C.S., Cenci M.A., Schulzer M., and Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (2000) 1365-1379
24. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. European Journal of Neuroscience 15 (2002) 120-132
25. Maratos E.C., Jackson M.J., Pearce R.K., and Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-dopa combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Movement Disorders 16 (2001) 631-641
26. Ming Y.L., Zhang H., Chen J., and Zhen X. SKF83959 stimulates Ca2+ signaling in primary cultured hippocampal neurons. Journal of Neurochemistry 98 (2006) 1316-1323
27. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 (1990) 340-345
28. Nutt J.G., Carter J.H., Lea E.S., and Woodward W.R. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Movement Disorders 12 (1997) 285-292
29. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., Hallett M., Hornykiewicz O., Jenner P., Katzenschlager R., Langston W.J., LeWitt P., Melamed E., Mena M.A., Michel P.P., Mytilineou C., Obeso J.A., Poewe W., Quinn N., Raisman-Vozari R., Rajput A.H., Rascol O., Sampaio C., and Stocchi F. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders 19 (2004) 997-1005
30. O'Sullivan G.J., Kinsella A., Sibley D.R., Tighe O., Croke D.T., and Waddington J.L. Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions. Synapse 55 (2005) 201-211
31. 3H]phosphatidylinositol 4,5-bisphosphate hydrolysis in postmortem human brain membranes and characterization of stimulation by dopamine D1 receptors. Journal of Neurochemistry 69 (1997) 639-644
32. Pavón N., Martín A.B., Mendialdua A., and Moratalla R. ERK Phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biological Psychiatry 59 (2006) 64-74
33. Pearce R.K., Jackson M., Smith L., Jenner P., and Marsden C.D. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Movement Disorders 10 (1995) 731-740
34. Pearce R.K., Jackson M., Britton D.R., Shiosaki K., Jenner P., and Marsden C.D. Actions of the D1 agonists A-77636 and A-89929 on locomotion and dyskinesia in MPTP-treated L-dopa primed common marmosets. Psychopharmacology (Berl.) 142 (1999) 51-60
35. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. The New England Journal of Medicine 342 (2000) 1484-1491
36. Rascol O., Nutt J.G., Blin O., Goetz C.G., Trugman J.M., Soubrouillard C., Carter J.H., Currie L.J., Fabre N., Thalamas C., Giardina W.W., and Wright S. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Archives of Neurology 58 (2001) 249-254
37. Rashid A.J., So C.H., Kong M.M., Furtak T., El-Ghundi M., Cheng R., O'Dowd B.F., and George S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proceedings of the National Academy of Sciences USA 104 (2007) 654-659
38. Syed N., Murphy J., Zimmerman Jr. T., Mark M.H., and Sage J.I. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Movement Disorders 13 (1998) 336-338
39. Taylor J.L., Bishop C., and Walker P.D. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacology. Biochemistry and Behavior 81 (2005) 887-893
40. Undie A.S., Weinstock J., Sarau H.M., and Friedman E. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. Journal of Neurochemistry 62 (1994) 2045-2048
41. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., and Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology (Berl.) 181 (2005) 611-638
42. Wirtshafter D., and Osborn C.V. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. European Journal of Pharmacology 528 (2005) 88-94
43. Zhen X., Torres C., Cai G., and Friedman E. Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's disease. Molecular Pharmacology 62 (2002) 1356-1363
44. Zhen X., Goswami S., Abdali S., Gil M., Bakshi K., and Friedman E. Regulation of cyclin-dependent kinase 5 and calcium/calmodulin-dependent protein kinase II by phosphatidylinositol-linked dopamine receptor in rat. Molecular Pharmacology 66 (2004) 1500-1507
45. Zhen X., Goswami S., and Friedman E. The role of the phosphatidylinositol-linked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacology. Biochemistry and Behavior 80 (2005) 597-601